中国骨与关节损伤杂志

参考文献

[1]Whitlock RP,Sun JC,Fremes SE,et al.Antithrombotic and thrombolytic therapy for valvular disease:antithrombotic therapy and prevention of thrombosis,9th:American college of chest physicians evidence-based clinical practice guidelines[J].Chest,2012,141(2 Suppl):e576S-e600S.

[2]Stein PD,Matta F.Epidemiology and incidence:the scope of the problem and risk factors for development of venous thromboembolism[J].Clin Chest Med,2010,31(4):611-628.

[3]张海波,何炜.骨科下肢深静脉血栓防治的经验及教训[J].中国骨与关节损伤杂志,2012,27(2):185-186.

[4]Boissier C,Lacroix P,College des enseignants de medicine vasculaire.Deep venous thrombosis and pulmonary embolism[J].Rev Prat,2012,62(10):1447-1455.

[5]高化,王宝军,赵亮,等.骨科下肢手术围手术期形成静脉血栓的流行病学研究[J].中国骨与关节损伤杂志,2013,28(5):488-489.

[6]Genet GF,Ostrowski SR,Sorensen AM,et al.Detection of t PA-induced hyperfibrinolysis in whole blood by Rapid TEG,Kaolin TEG,and functional fibrinogen TEG in healthy individuals[J].Clin Appl Thromb Hemost,2012,18(6):638-644.

[7]Coleman DM,Wakefield TW.Biomarkers for the diagnosis of deep vein thrombosis[J].Expert Opin Med Diagn,2012,6(4):253-257.

[8]Falck-Ytter Y,Francis CW,Johanson NA,et al.Prevention of VTE in orthopedic surgery patients:antithrombotic therapy and prevention of thrombosis,9th ed:American college of chest physicians evidence-based clinical practice guidelines[J].Chest,2012,141(2 Suppl):e278S-325S.

[9]Kakkar AK,Brenner B,Dahl OE,et al.Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind,randomised controlled trial[J].Lancet,2008,372(9632):31-39.

[10]Buller HR.Oral rivaroxaban for the treatment of symptomatic venous thromboembolism:a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies[C].2012.

[11]Prins MH,Lensing AW,Bauersachs R,et al.Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism:a pooled analysis of the EINSTEIN-DVT and PE randomized studies[J].Thromb J,2013,11(1):21.

[12]中华医学会骨科学分会.中国骨科大手术静脉血栓栓塞症预防指南[J/CD].中华关节外科杂志:电子版,2009,3(3):70-72.

[13]Lassen MR,Raskob GE,Gallus A,et al.Apixaban versus enoxaparin for thromboprophylaxis after knee replacement(ADVANCE-2):a randomised double-blind trial[J].Lancet,2010,375(9717):807-815.

[14]Lassen MR,Gallus A,Raskob GE,et al.Apixaban versus enoxaparin for thromboprophylaxis after hip replacement[J].N Engl J Med,2010,363(26):2487-2498.

[15]Agnelli G,Buller HR,Cohen A,et al.Apixaban for extended treatment of venous thromboembolism[J].N Engl J Med,2013,368(8):699-708.

[16]中华医学会放射学分会介入学组.下肢深静脉血栓形成介入治疗规范的专家共识[J].中华放射学杂志,2011,45(3):294-296.

[17]中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南(第2版)[J].中华外科杂志,2012,50(7):611-614.

[18]Comerota AJ.Thrombolysis for deep venous thrombosis[J].J Vasc Surg,2012,55(2):607-611.

[19]Enden T,Haig Y,Klow NE,et al.Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis(the Ca Ven T study):a randomised controlled trial[J].Lancet,2012,379(9810):31-38.

[20]Holper P,Kotelis D,Attigah N,et al.Longterm results after surgical thrombectomy and simultaneous stenting for symptomatic iliofemoral venous thrombosis[J].Eur J Vasc Endovasc Surg,2010,39(3):349-355.